1Hurwitz JL,McCoy F,Scullin P. New advances in the second-line treatment of small cell lung cancer[J].Oncologist(The),2009,(10):986-994.
2Spira A,Ettinger DS. Multidisciplinary management of lung cancer[J].New England Journal of Medicine,2004,(04):379-392.
3Murray N,Turrisi AT 3rd. A review of first-line treatment for small-cell lung cancer[J].JOURNAL OF THORACIC ONCOLOGY,2006,(03):270-278.
4Navada S,Lai P,Schwartz A. Temporal trends in small cell lung cancer:Analysis of the national Surveillance,Epidemiology,and End-Results (SEER) database[J].Journal of Clinical Oncology,2006,(18Suppl):7082.
5Rossi A,Di Maio M,Chiodini P. Carboplatin-or CisplatinBased Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer:The COCIS Meta-Analysis of Individual Patient Data[J].Journal of Clinical Oncology,2012,(14):1692-1698.
6Hanna N,Bunn PA Jr,Langer C. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J].Journal of Clinical Oncology,2006,(13):2038-2043.
7Hermes A,Bergman B,Bremnes R. A randomized phase Ⅲ trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer,extensive disease (SCLCED):IRIS-Study[J].Journal of Clinical Oncology,2007,(18S):7523.
8Syrigos K,Katirtzoglou N,Charpidou A. Irinotecan,carboplatin and etoposide regimen in extensive disease small cell lung cancer:Phase Ⅱ trial[J].Journal of Clinical Oncology,2007,(18S):18153.
9Schmittel AH,Sebastian M,Fischer yon Weikersthal L. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer:Results of the German randomized phase Ⅲ trial[J].Journal of Clinical Oncology,2009,(Suppl):8029.
10Ohe Y,Negoro S,Matsui K. Phase Ⅰ-Ⅱ study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer[J].Annals of Oncology,2005,(03):430-436.doi:10.1093/annonc/mdi081.
二级参考文献38
1Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.JpnJ Cancer Res, 1998, 89(11): 1229-1238.
2Yamamoto M, Takakura A, Masuda N. Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin. Drug Des Devel Ther, 2009, 2: 189-192.
3Chirag MS. Amrubicin: a synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer. Recent Pat Anticancer Drug Discov, 2009, 4(3): 241-245.
4Noguchi T, Ichii S, Morisada S, et al. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res, 1998, 89(10): 1055-1060.
5Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline and its active metabolite amrubicinol on human tumor cells.JpnJ Cancer Res, 1998, 89(10): 1067-1073.
6Matsunaga Y, Hamada A, Okamoto I, et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit, 2006, 28(1): 76-82.
7Noda T, Watanabe T, Kohda A, et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs, 1998, 16(2): 121 - 128.
8Hanada M, Noguchi T, Yamaoka T. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Sci, 2007, 98(3): 447-454.
9Takigawa N, Takeyama M, Shibayama T, et al. The combination effect of amrubicin with cisplatin or irinotecan for smaLl-ceU lung cancer cells. Oncol Rep, 2006, 15(4): 837-842.
10Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study; Invest New Drugs, 2007, 25(3): 253-258.
